Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Activists have sharply criticised the US government’s move to exclude South Africa from receiving HIV prevention medication ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Lenacapavir is an injectable medicine that only needs to be taken twice a year, making it easier to use than daily HIV pills.

Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline ...

Long-term, low doses of THC mitigate many harmful side effects and inflammation caused by HIV and antiretroviral therapy (ART), according to new research from Texas Biomedical Research Institute.